Current Problems in Cancer
Volume 32, Issue 2 , Pages 43-87 , March 2008

Cutaneous Lymphoma

  • Benjamin D. Smith, MD

      Affiliations

    • Major, USAF Medical Corps, Wilford Hall Medical Center, Lackland AFB, Texas
    • Adjunct Assistant Professor, Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas
    • ,
  • Lynn D. Wilson, MD, MPH

      Affiliations

    • Professor and Vice-Chairman, Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut

References 

  1. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92(15):1240–1251
  2. Smith BD, Jones G, Wilson LD. Chapter 76: Mycosis fungoides. In:  Gunderson LL,  Tepper JE editor. Clinical Radiation Oncology. Philadelphia, PA: Churchill Livingstone; 2007;p. 1773–1797
  3. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785
  4. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007;143(7):854–859
  5. Smith BD, Smith GL, Cooper DL, Wilson LD. The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry. J Clin Oncol. 2005;23(15):3390–3395
  6. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90(1):354–371
  7. Morales-Suarez-Varela MM, Olsen J, Johansen P, Kaerlev L, Guenel P, Arveux P, et al. Occupational exposures and mycosis fungoides (A European multicentre case-control study). Cancer Causes Control. 2005;16(10):1253–1259(Europe)
  8. Herne KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome. Blood. 2003;101(6):2132–2136
  9. Pancake BA, Wassef EH, Zucker-Franklin D. Demonstration of antibodies to human T-cell lymphotropic virus-I tax in patients with the cutaneous T-cell lymphoma, mycosis fungoides, who are seronegative for antibodies to the structural proteins of the virus. Blood. 1996;88(8):3004–3009
  10. Shohat M, Hodak E, Hannig H, Bodemer W, David M, Shohat B. Evidence for the cofactor role of human T-cell lymphotropic virus type 1 in mycosis fungoides and Sezary syndrome. Br J Dermatol. 1999;141(1):44–49
  11. Gupta RK, Ramble J, Tong CY, Whittaker S, MacMahon E. Cytomegalovirus seroprevalence is not higher in patients with mycosis fungoides/Sezary syndrome. Blood. 2006;107(3):1241–1242
  12. Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. J Am Acad Dermatol. 2002;47(6):914–918
  13. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053–1063
  14. Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46(1):95–106
  15. de Coninck EC, Kim YH, Varghese A, Hoppe RT. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol. 2001;1(3):779–784
  16. Sibaud V, Beylot-Barry M, Thiebaut R, Parrens M, Vergier B, Delaunay M, et al. Bone marrow histopathologic and molecular staging in epidermotropic T-cell lymphomas. Am J Clin Pathol. 2003;119(3):414–423
  17. Graham SJ, Sharpe RW, Steinberg SM, Cotelingam JD, Sausville EA, Foss FM. Prognostic implications of a bone marrow histopathologic classification system in mycosis fungoides and the Sezary syndrome. Cancer. 1993;72(3):726–734
  18. Smith BD, Wilson LD. Management of mycosis fungoides (Part 1. Diagnosis, staging, and prognosis). Oncology. 2003;17(9):1281–1288
  19. Yazdi AS, Medeiros LJ, Puchta U, Thaller E, Flaig MJ, Sander CA. Improved detection of clonality in cutaneous T-cell lymphomas using laser capture microdissection. J Cutan Pathol. 2003;30(8):486–491
  20. Gellrich S, Lukowsky A, Schilling T, Rutz S, Muche JM, Jahn S, et al. Microanatomical compartments of clonal and reactive T cells in mycosis fungoides: molecular demonstration by single cell polymerase chain reaction of T cell receptor gene rearrangements. J Invest Dermatol. 2000;115(4):620–624
  21. Santucci M, Biggeri A, Feller AC, Massi D, Burg G. Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC cutaneous lymphoma study group investigation (European Organization for Research and Treatment of Cancer). Am J Surg Pathol. 2000;24(1):40–50
  22. Kohler S, Kim YH, Smoller BR. Histologic criteria for the diagnosis of erythrodermic mycosis fungoides and Sezary syndrome: a critical reappraisal. J Cutan Pathol. 1997;24(5):292–297
  23. Fung MA, Murphy MJ, Hoss DM, Grant-Kels JM. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol. 2002;46(3):325–357
  24. Delfau-Larue MH, Laroche L, Wechsler J, Lepage E, Lahet C, Asso-Bonnet M, et al. Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood. 2000;96(9):2987–2992
  25. Wood GS, Tung RM, Haeffner AC, Crooks CF, Liao S, Orozco R, et al. Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol. 1994;103(1):34–41
  26. Ashton-Key M, Diss TC, Du MQ, Kirkham N, Wotherspoon A, Isaacson PG. The value of the polymerase chain reaction in the diagnosis of cutaneous T-cell infiltrates. Am J Surg Pathol. 1997;21(7):743–747
  27. Dadej K, Gaboury L, Lamarre L, Petorin C, Seguin C, Cadotte M, et al. The value of clonality in the diagnosis and follow-up of patients with cutaneous T-cell infiltrates. Diagn Mol Pathol. 2001;10(2):78–88
  28. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood. 1998;92(4):1150–1159
  29. Vergier B, de Muret A, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases (French Study Group of Cutaneous Lymphomas). Blood. 2000;95(7):2212–2218
  30. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC Cancer Staging Handbook. Sixth Edition. New York, NY: Springer; 2002;
  31. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–1722
  32. Tsai EY, Taur A, Espinosa L, Quon A, Johnson D, Dick S, et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol. 2006;142(5):577–584
  33. Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides (A long- term outcome analysis). Arch Dermatol. 1996;132(11):1309–1313
  34. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol. 1999;135(1):26–32
  35. Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Semin Oncol. 1999;26(3):276–289
  36. Vonderheid EC, Diamond LW, van Vloten WA, Scheffer E, Meijer CJ, Cashell AW, et al. Lymph node classification systems in cutaneous T-cell lymphoma (Evidence for the utility of the Working Formulation of Non-Hodgkin’s Lymphomas for Clinical Usage). Cancer. 1994;7(1):207–218
  37. Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sezary syndrome. J Am Acad Dermatol. 1999;40:914–924
  38. Wasik MA, Vonderheid EC, Bigler RD, Marti R, Lessin SR, Polansky M, et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma (Clinical and prognostic implications). Arch Dermatol. 1996;132(1):42–47
  39. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol. 1995;32(3):448–453
  40. Quiros PA, Kacinski BM, Wilson LD. Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T-cell lymphoma treated with total skin electron beam radiation therapy. Cancer. 1996;77(9):1912–1917
  41. Delfau-Larue MH, Dalac S, Lepage E, Petrella T, Wechsler J, Farcet JP, et al. Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides. Blood. 1998;92(9):3376–3380
  42. Guitart J, Camisa C, Ehrlich M, Bergfeld WF. Long-term implications of T-cell receptor gene rearrangement analysis by Southern blot in patients with cutaneous T-cell lymphoma. J Am Acad Dermatol. 2003;48(5):775–779
  43. Beylot-Barry M, Sibaud V, Thiebaut R, Vergier B, Beylot C, Delaunay M, et al. Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas. J Invest Dermatol. 2001;117(4):920–926
  44. Bakels V, Van Oostveen JW, Geerts ML, Gordijn RL, Walboomers JM, Scheffer E, et al. Diagnostic and prognostic significance of clonal T-cell receptor beta gene rearrangements in lymph nodes of patients with mycosis fungoides. J Pathol. 1993;170(3):249–255
  45. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002;138(2):191–198
  46. Kaye FJ, Bunn PA, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989;321(26):1784–1790
  47. Stadler R, Otte HG, Luger T, Henz BM, Kuhl P, Zwingers T, et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood. 1998;92(10):3578–3581
  48. Wilson LD, Kacinski BM, Jones GW. Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (Mycosis Fungoides). Int J Radiat Oncol Biol Phys. 1998;40(1):109–115
  49. Jones G, Wilson LD, Fox-Goguen L. Total skin electron beam radiotherapy for patients who have mycosis fungoides. Hematol Oncol Clin North Am. 2003;17(6):1421–1434
  50. Chinn DM, Chow S, Kim YH, Hoppe RT. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys. 1999;43(5):951–958
  51. Quiros PA, Jones GW, Kacinski BM, Braverman IM, Heald PW, Edelson RL, et al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys. 1997;38(5):1027–1035
  52. Molina A, Zain J, Arber DA, Angelopolou M, O’Donnell M, Murata-Collins J, et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol. 2005;23(25):6163–6171
  53. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139(2):165–173
  54. Esteve E, Bagot M, Joly P, Souteyrand P, Beylot-Barry M, Vaillant L, et al. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas (French Study Group of Cutaneous Lymphomas). Arch Dermatol. 1999;135(11):1349–1353
  55. Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989;20(3):416–428
  56. Licata AG, Wilson LD, Braverman IM, Feldman AM, Kacinski BM. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma (The influence of additional therapy after total skin electron beam radiation). Arch Dermatol. 1995;131(4):432–435
  57. Zackheim HS, Epstein EH, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol. 1990;22(5 Pt 1):802–810
  58. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides (Experience in 79 patients). Arch Dermatol. 1998;134(8):949–954
  59. Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002;47(5):672–684
  60. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138(3):325–332
  61. Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801–815
  62. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy (Preliminary results). N Engl J Med. 1987;316(6):297–303
  63. Weber F, Schmuth M, Sepp N, Fritsch P. Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides. Acta Derm Venereol. 2005;85(4):329–332
  64. Young AR. Carcinogenicity of UVB phototherapy assessed. Lancet. 1995;345(8962):1431–1432
  65. Abel EA, Sendagorta E, Hoppe RT. Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides. J Am Acad Dermatol. 1986;14(6):1029–1038
  66. Ramsay DL, Lish KM, Yalowitz CB, Soter NA. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol. 1992;128(7):931–933
  67. Diederen PV, van Weelden H, Sanders CJ, Toonstra J, van Vloten WA. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol. 2003;48(2):215–219
  68. Herrmann JJ, Roenigk HH, Hurria A, Kuzel TM, Samuelson E, Rademaker AW, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol. 1995;33(2 Pt 1):234–242
  69. Honigsmann H, Brenner W, Rauschmeier W, Konrad K, Wolff K. Photochemotherapy for cutaneous T cell lymphoma (A follow-up study). J Am Acad Dermatol. 1984;10(2 Pt 1):238–245
  70. Kuzel TM, Roenigk HH, Samuelson E, Herrmann JJ, Hurria A, Rademaker AW, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol. 1995;13(1):257–263
  71. Chiarion-Sileni V, Bononi A, Fornasa CV, Soraru M, Alaibac M, Ferrazzi E, et al. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer. 2002;95(3):569–575
  72. Micaily B, Miyamoto C, Kantor G, Lessin S, Rook A, Brady L, et al. Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys. 1998;42(2):361–364
  73. Wong R, Jones G, Farrar N, Sur R, Wilson L. Local superficial radiotherapy (LSRT) for newly diagnosed stage IA patch-plaque mycosis fungoides (MF) with only one, two, or three presenting lesions. Int J Radiat Oncol Biol Phys. 2003;57(2):S289–S290(suppl 1)
  74. Cotter GW, Baglan RJ, Wasserman TH, Mill W. Palliative radiation treatment of cutaneous mycosis fungoides: a dose response. Int J Radiat Oncol Biol Phys. 1983;9(10):1477–1480
  75. Jones GW, Kacinski BM, Wilson LD, Willemze R, Spittle M, Hohenberg G, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol. 2002;47(3):364–370
  76. Hoppe RT, Fuks Z, Bagshaw MA. The rationale for curative radiotherapy in mycosis fungoides. Int J Radiat Oncol Biol Phys. 1977;2(9-10):843–851
  77. Jones GW, Tadros A, Hodson DI, Rosenthal D, Roberts J, Thorson B. Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY. Int J Radiat Oncol Biol Phys. 1994;28(4):839–845
  78. Jones GW, Hoppe RT, Glatstein E. Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9(5):1057–1076
  79. Chen Z, Agostinelli AG, Wilson LD, Nath R. Matching the dosimetry characteristics of a dual-field Stanford technique to a customized single-field Stanford technique for total skin electron therapy. Int J Radiat Oncol Biol Phys. 2004;59(3):872–885
  80. Gamble LM, Farrell TJ, Jones GW, Hayward JE. Composite depth dose measurement for total skin electron (TSE) treatments using radiochromic film. Phys Med Biol. 2003;48(7):891–898
  81. Anacak Y, Arican Z, Bar-Deroma R, Tamir A, Kuten A. Total skin electron irradiation: evaluation of dose uniformity throughout the skin surface. Med Dosim. 2003;28(1):31–34
  82. Jones GW, Rosenthal D, Wilson LD. Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome). Cancer. 1999;85(9):1985–1995
  83. Wilson LD, Quiros PA, Kolenik SA, Heald PW, Braverman IM, Edelson RL, et al. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996;35(1):69–73
  84. Becker M, Hoppe RT, Knox SJ. Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys. 1995;32(5):1445–1449
  85. Wilson LD, Jones GW, Kim D, Rosenthal D, Christensen IR, Edelson RL, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol. 2000;43(1 Pt 1):54–60
  86. Rook AH, Kuzel TM, Olsen EA. Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am. 2003;17(6):1435–1448ix
  87. Price NM. Electron beam therapy (Its effect on eccrine gland function in mycosis fungoides patients). Arch Dermatol. 1979;115(9):1068–1070
  88. Desai KR, Pezner RD, Lipsett JA, Vora NL, Luk KH, Wong JY, et al. Total skin electron irradiation for mycosis fungoides: relationship between acute toxicities and measured dose at different anatomic sites. Int J Radiat Oncol Biol Phys. 1988;15(3):641–645
  89. Ross C, Tingsgaard P, Jorgensen H, Vejlsgaard GL. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol. 1993;51(2):63–72
  90. Jumbou O, N′Guyen JM, Tessier MH, Legoux B, Dreno B. Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol. 1999;140(3):427–431
  91. Roenigk HH, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol. 1990;95(6):198S–205S(suppl)
  92. Wollina U, Looks A, Meyer J, Knopf B, Koch HJ, Liebold K, et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J Am Acad Dermatol. 2001;44(2):253–260
  93. Thomsen K, Hammar H, Molin L, Volden G. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage (A report from the Scandinavian Mycosis Fungoides Group). Acta Derm Venereol. 1989;69(6):536–538
  94. Jones G, McLean J, Rosenthal D, Roberts J, Sauder DN. Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). J Am Acad Dermatol. 1992;26(6):960–967
  95. Duvic M. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Oncology. 2007;21(2):33–40(Williston Park), (suppl 1)
  96. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced- stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456–2471
  97. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T- cell lymphoma. Arch Dermatol. 2001;137(5):581–593
  98. Porcu P, Baiocchi R, Buckner M. Bexarotene-induced T-cell immunomodulation and response in CTCL. Blood. 2004;104:744
  99. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19(2):376–388
  100. Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol. 2006;126(3):575–583
  101. Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox. ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma. 2001;1(4):298–302
  102. Lim HW, Edelson RL. Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9(5):1117–1126
  103. Heald P, Rook A, Perez M, Wintroub B, Knobler R, Jegasothy B, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol. 1992;27(3):427–433
  104. Wilson LD, Licata AL, Braverman IM, Edelson RL, Heald PW, Feldman AM, et al. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys. 1995;32(4):987–995
  105. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol. 2005;125(5):1045–1052
  106. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid. SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–39
  107. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–3115
  108. Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol. 1996;34(4):626–631
  109. Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003;98(5):993–1001
  110. Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000;18(13):2603–2606
  111. Bigler RD, Crilley P, Micaily B, Brady LW, Topolsky D, Bulova S, et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant. 1991;7(2):133–137
  112. Russell-Jones R, Child F, Olavarria E, Whittaker S, Spittle M, Apperley J. Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival. Ann N Y Acad Sci. 2001;941:147–154
  113. Sterling JC, Marcus R, Burrows NP, Roberts SO. Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exp Dermatol. 1995;20(1):73–75
  114. Soligo D, Ibatici A, Berti E, Morandi P, Longhi E, Venegoni L, et al. Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen. Bone Marrow Transplant. 2003;31(8):663–666
  115. Wilson LD, Cooper DL, Goodrich AL, Friedman ND, Feldman AM, Braverman IM, et al. Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy. Int J Radiat Oncol Biol Phys. 1994;28(4):829–837
  116. Sander CA, Flaig MJ, Jaffe ES. Cutaneous manifestations of lymphoma: a clinical guide based on the WHO classification. Clin Lymphoma. 2001;2(2):86–100discussion 101-2
  117. LeBoit PE. Granulomatous slack skin. Dermatol Clin. 1994;12(2):375–389
  118. Querfeld C, Kuzel TM, Guitart J, Rosen ST. Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy. Oncology. 2007;21(6):689–696(Williston Park), discussion 699-700
  119. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49(6):1049–1058
  120. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol. 2000;18(15):2908–2925
  121. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House (Virginia, November 1997). J Clin Oncol. 1999;17(12):3835–3849
  122. Smith BD, Glusac EJ, McNiff JM, Smith GL, Heald PW, Cooper DL, et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol. 2004;22(4):634–639
  123. Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479–484
  124. Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, van Baarlen J, Blokx WA, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007;25(12):1581–1587
  125. Grange F, Beylot-Barry M, Courville P, Maubec E, Bagot M, Vergier B, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144–1150
  126. Eich HT, Eich D, Micke O, Suttzer H, Casper C, Krieg T, et al. Long-term efficacy, curative potential, and prognostic factors of radiotherapy in primary cutaneous B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2003;55(4):899–906
  127. Bekkenk MW, Vermeer MH, Geerts ML, Noordijk EM, Heule F, van Voorst Vader PC, et al. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. J Clin Oncol. 1999;17(8):2471–2478
  128. Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature. Leuk Lymphoma. 2006;47(9):1902–1907
  129. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52(5):847–853
  130. Santucci M, Pimpinelli N, Arganini L. Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma (Clinicopathologic and immunologic study of 83 cases). Cancer. 1991;67(9):2311–2326
  131. Rijlaarsdam JU, Toonstra J, Meijer OW, Noordijk EM, Willemze R. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy. J Clin Oncol. 1996;14(2):549–555
  132. Kirova YM, Piedbois Y, Le Bourgeois JP. Radiotherapy in the management of cutaneous B-cell lymphoma (Our experience in 25 cases). Radiother Oncol. 1999;52(1):15–18
  133. Piccinno R, Caccialanza M, Berti E. Dermatologic radiotherapy of primary cutaneous follicle center cell lymphoma. Eur J Dermatol. 2003;13(1):49–52
  134. Smith BD, Wilson LD. Management of mycosis fungoides (Part 2. Treatment). Oncology. 2003;17(10):1419–1428discussion 30, 33
  135. Smith BD, Wilson LD. Cutaneous lymphomas. Semin Radiat Oncol. 2007;17(3):158–168

PII: S0147-0272(07)00073-6

doi: 10.1016/j.currproblcancer.2007.12.002

Current Problems in Cancer
Volume 32, Issue 2 , Pages 43-87 , March 2008

Article Tools

* Image Usage & Resolution